The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic significance of new glioma marker, laminin-411, and its inhibition by targeted nanobiopolymer in vivo.
J. Y. Ljubimova
Stock Ownership - Arrogene
S. Inoue
Stock Ownership - Keith Black
S. I. Bannykh
No relevant relationships to disclose
S. Phuphanich
No relevant relationships to disclose
J. Rudnick
No relevant relationships to disclose
A. V. Ljubimov
Stock Ownership - Arrogene
K. L. Black
Stock Ownership - Arrogene; ImmunoCellular Therapeutics; Neurovision